Evidence Grade E — Very limited evidence. 5 published studies. 0 registered clinical trials.
Medically reviewed by a licensed medical professional
Prostamax is a synthetic tetrapeptide from the Khavinson bioregulator programme, proposed to target prostate tissue. No human clinical trials have been conducted. An animal study (60 rats) in a prostate inflammation model has been reported. It has no regulatory approval.
Prostamax is also known by these brand and alternate names:
5 published studies: 4 human, 1 animal, 0 in-vitro, 0 reviews
Prostamax has no marketing authorisation from any major regulatory agency. No human clinical trials have been conducted. An animal study (60 rats) comparing Prostamax against existing prostate treatments in a chronic prostatitis model has been reported, but this is a single preclinical study.
As with other Khavinson bioregulator peptides, the proposed tissue-specific targeting mechanisms have not been independently validated. Products available through unregulated channels lack pharmaceutical quality assurance.
Research from the Khavinson group proposes that Prostamax may promote chromatin decondensation in prostate tissue through epigenetic regulation. Molecular modelling suggests potential interactions with amino acid transporters. These proposed mechanisms are computational predictions and have not been experimentally confirmed in human tissue.
Only 2-3 peer-reviewed studies directly on Prostamax exist. The primary animal study was published in a minor journal with no blinding described. No human clinical trials, no pharmacokinetic data, no dose-response studies, and no independent replication exist. Computational modelling suggests potential molecular interactions but these predictions have not been experimentally confirmed. Products from unregulated channels lack pharmaceutical quality assurance.
PeptideTrace tracks 0 registered clinical trials for Prostamax sourced from ClinicalTrials.gov.
No trials registered on ClinicalTrials.gov for this compound.
Prostamax is a synthetic tetrapeptide bioregulator with the sequence Lys-Glu-Asp-Pro (KEDP). Its molecular weight is 487.5 Da with the molecular formula C20H33N5O9 (PubChem CID 9848296). Developed by Vladimir Khavinson as part of the cytomedine program, Prostamax targets prostate tissue. No confirmed CAS number has been identified. No pharmacokinetic data exist. Available as a dietary supplement in Russia.
Research suggests Prostamax promotes chromatin decondensation through epigenetic regulation, making previously silenced gene regions accessible for transcription. Molecular modeling demonstrates enhanced binding efficiency to LAT1, LAT2, and PEPT1 transporters compared to known substrates, facilitating cellular uptake. Studies in lymphocytes from elderly human subjects showed increased frequency of sister chromatid exchanges, heightened nucleolus organizer regions, and decreased pericentromeric heterochromatin segments. No classical receptor binding has been described.
A chronic aseptic prostatitis model (Borovskaya et al. 2013, N=60 Wistar rats) compared Prostamax 20 microg/kg IM against Samprost (prostate extract) and Prostamol Uno (Serenoa repens). Prostate density decreased from 1.05 to 0.98 g/cm3 (p<=0.05). Prostamax reduced chronic inflammation signs and prevented sclerotic and atrophic prostate changes. Lymphocyte chromatin studies (Meskhi et al. 2004; Dzhokhadze et al. 2012) demonstrated deheterochromatinization of chromatin in lymphocytes from elderly subjects.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Compare prices from 6 vendor listings
View pricing data across vendors and countries for Prostamax
Carbetocin has not been approved by the FDA. It is registered in over 80 countries for prevention of uterine atony and excessive bleeding after caesarean delivery. A heat-stable formulation was added to the WHO Essential Medicines List in 2019. The CHAMPION trial (WHO, 2018; over 29,000 women) compared a heat-stable carbetocin formulation to oxytocin for preventing postpartum haemorrhage after vaginal delivery, and found it to be non-inferior. The heat-stable formulation addresses a significant limitation of oxytocin, which degrades in warm climates without refrigeration — a major concern in low-resource settings where postpartum haemorrhage causes the most deaths. Its regulatory status varies by jurisdiction.
Nafarelin is marketed as Synarel (approved 1990) for endometriosis and central precocious puberty. It requires administration as one spray in each nostril twice daily — a higher frequency than injectable alternatives but avoids needles entirely, which can be a significant advantage for some patients, particularly children. Clinical trials showed symptom improvement in 75–92% of endometriosis patients. However, absorption can be affected by nasal congestion or concurrent use of nasal decongestants, which can be a practical limitation. As with all GnRH agonists, prolonged use leads to bone density loss, and treatment for endometriosis is typically limited to six months. Nafarelin occupies a niche for patients who prefer non-injectable hormone suppression, though it has become less commonly prescribed as longer-acting depot injections and oral alternatives have become available.
Triptorelin is marketed as Trelstar (approved 2000) for advanced prostate cancer, available as intramuscular depot injections in monthly (3.75 mg), three-monthly (11.25 mg), and six-monthly (22.5 mg) formulations. It is also widely used internationally for gender-affirming care and central precocious puberty. Triptorelin is one of the most commonly used GnRH agonists globally, though it faces the same competitive pressure as other agents in this class from newer oral GnRH antagonists like relugolix, which avoid the initial hormone flare and offer potential cardiovascular advantages. Clinical data demonstrate reliable testosterone suppression comparable to other GnRH agonists in this class.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
